Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 6.14% is in line with its 5-year average of 6.07%, near the high end of its 5-year range (-220.51%–19.95%).
15.57% below its 12-month average of 7.27%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 5.33%.
EBITDA MARGIN
6.14%
EBITDA MARGIN AVG TTM
7.27%
EBITDA MARGIN AVG 3Y
4.96%
EBITDA MARGIN AVG 5Y
6.07%
EBITDA MARGIN AVG 10Y
5.04%
EBITDA MARGIN AVG 15Y
5.56%
EBITDA MARGIN AVG 20Y
7.58%
CURRENT VS TTM AVG
-15.57%
CURRENT VS 3Y AVG
+23.83%
CURRENT VS 5Y AVG
+1.08%
CURRENT VS 10Y AVG
+21.72%
CURRENT VS 15Y AVG
+10.43%
CURRENT VS 20Y AVG
-18.97%
Harvard Bioscience, Inc.
Market Cap
$38.61M
EBITDA Margin
6.14%
TTM Avg
7.27%
3Y Avg
4.96%
5Y Avg
6.07%
Market Cap
$38.78M
EBITDA Margin
-359.76%
TTM Avg
-259.71%
3Y Avg
-233.72%
5Y Avg
-2126.07%
Market Cap
$37.93M
EBITDA Margin
-27375.58%
TTM Avg
-138216.12%
3Y Avg
-92142.37%
5Y Avg
-55460.65%
Market Cap
$39.64M
EBITDA Margin
-217.02%
TTM Avg
-395.41%
3Y Avg
-245.06%
5Y Avg
-171.96%
Market Cap
$36.21M
EBITDA Margin
-29.82%
TTM Avg
-228.84%
3Y Avg
-176.67%
5Y Avg
-120.12%
Market Cap
$35.84M
EBITDA Margin
-136.01%
TTM Avg
-1016.71%
3Y Avg
-1237.80%
5Y Avg
-1237.80%
Market Cap
$35.84M
EBITDA Margin
-1929.22%
TTM Avg
-1308.49%
3Y Avg
-1783.80%
5Y Avg
-1343.37%
Market Cap
$35.52M
EBITDA Margin
-22.75%
TTM Avg
-133.81%
3Y Avg
-3828.74%
5Y Avg
-3288.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harvard Bioscience, Inc. (HBIO) | $38.61M | 6.14% | 7.27% | 4.96% | 6.07% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $38.78M | -359.76% | -259.71% | -233.72% | -2126.07% |
| Incannex Healthcare Limited (IXHL)vs › | $37.93M | -27375.58% | -138216.12% | -92142.37% | -55460.65% |
| Veru Inc. (VERU)vs › | $39.64M | -217.02% | -395.41% | -245.06% | -171.96% |
| EUDA Health Holdings Limited (EUDA)vs › | $36.21M | -29.82% | -228.84% | -176.67% | -120.12% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | -136.01% | -1016.71% | -1237.80% | -1237.80% |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | -1929.22% | -1308.49% | -1783.80% | -1343.37% |
| DocGo Inc. (DCGO)vs › | $35.76M | -22.81% | -7.79% | -0.80% | -0.97% |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | -22.75% | -133.81% | -3828.74% | -3288.72% |
| Precipio, Inc. (PRPO)vs › | $41.83M | 2.29% | -7.32% | -44.00% | -66.61% |
Gross Margin
58.2%
EBITDA Margin
6.1%
Operating Margin
1.2%
Net Margin
-11.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 5.33% |
| 2026-03-31 | 5.93% |
| 2025-12-31 | 13.81% |
| 2025-09-30 | 7.39% |
| 2025-06-30 | 3.91% |
| 2025-03-31 | -220.51% |
| 2024-12-31 | 7.21% |
| 2024-09-30 | -0.27% |
| 2024-06-30 | -1.16% |
| 2024-03-31 | -2.03% |
| 2023-12-31 | 7.30% |
| 2023-09-30 | 3.34% |
| 2023-06-30 | 8.75% |
| 2023-03-31 | 11.58% |
| 2022-12-31 | 5.29% |
| 2022-09-30 | -6.78% |
| 2022-06-30 | 19.95% |
| 2022-03-31 | -16.90% |
| 2021-12-31 | 10.95% |
| 2021-09-30 | 8.18% |
| 2021-06-30 | 6.74% |
| 2021-03-31 | 6.19% |
| 2020-12-31 | 15.09% |
| 2020-09-30 | 8.45% |
| 2020-06-30 | 10.76% |
| 2020-03-31 | -5.73% |
| 2019-12-31 | 11.56% |
| 2019-09-30 | 0.21% |
| 2019-06-30 | 5.62% |
| 2019-03-31 | 5.19% |
| 2018-12-31 | 9.28% |
| 2018-09-30 | 9.73% |
| 2018-06-30 | 5.06% |
| 2018-03-31 | 1.44% |
| 2017-12-31 | 4.70% |
| 2017-09-30 | 3.38% |
| 2017-06-30 | 3.84% |
| 2017-03-31 | 1.14% |
| 2016-12-31 | -1.89% |
| 2016-09-30 | 1.15% |
| 2016-06-30 | 1.06% |
| 2016-03-31 | 3.14% |
| 2015-12-31 | 2.80% |
| 2015-09-30 | 1.08% |
| 2015-06-30 | 4.11% |
| 2015-03-31 | 0.05% |
| 2014-12-31 | 9.42% |
| 2014-09-30 | 9.28% |
| 2014-06-30 | 9.81% |
| 2014-03-31 | 8.81% |
| 2013-12-31 | 16.08% |
| 2013-09-30 | -0.39% |
| 2013-06-30 | 0.89% |
| 2013-03-31 | 3.49% |
| 2012-12-31 | 6.81% |
| 2012-09-30 | 2.31% |
| 2012-06-30 | 7.06% |
| 2012-03-31 | 6.73% |
| 2011-12-31 | 8.35% |
| 2011-09-30 | 3.51% |
| 2011-06-30 | 13.04% |
| 2011-03-31 | 9.77% |
| 2010-12-31 | 13.17% |
| 2010-09-30 | 9.59% |
| 2010-06-30 | 12.50% |
| 2010-03-31 | 13.33% |
| 2009-12-31 | 14.30% |
| 2009-09-30 | 12.61% |
| 2009-06-30 | 8.45% |
| 2009-03-31 | 15.61% |
| 2008-12-31 | 17.88% |
| 2008-09-30 | 13.06% |
| 2008-06-30 | 10.92% |
| 2008-03-31 | 10.59% |
| 2007-12-31 | 14.86% |
| 2007-09-30 | 14.95% |
| 2007-06-30 | 16.63% |
| 2007-03-31 | 16.08% |
| 2006-12-31 | 14.91% |
| 2006-09-30 | 14.07% |
| 2006-06-30 | 17.32% |
| 2006-03-31 | 17.14% |
| 2005-12-31 | 17.76% |
| 2005-09-30 | 20.43% |
| 2005-06-30 | -99.24% |
| 2005-03-31 | 9.51% |
| 2004-12-31 | 14.78% |
| 2004-09-30 | 12.71% |
| 2004-06-30 | 10.54% |
| 2004-03-31 | 7.89% |
| 2003-12-31 | 16.87% |
| 2003-09-30 | 13.66% |
| 2003-06-30 | 15.61% |
| 2003-03-31 | 12.82% |
| 2002-12-31 | -1.88% |
| 2002-09-30 | 8.24% |
